Effect of Campath-1H antibody on human hematopoietic progenitors in vitro.
Affiliation
Department of Experimental Haematology, CRC Paterson Institute for Cancer Research, Withington, Manchester, England.Issue Date
1993-08-01
Metadata
Show full item recordAbstract
The humanized antibody CAMPATH-1H has been shown in pilot studies to be beneficial in the treatment of lymphoid malignancy and other lymphoproliferative diseases. The antigen recognized by this antibody is not confined to lymphoid cells, and work with rat antibodies of similar specificity has not eliminated the possibility of damage to human hematopoietic progenitors, particularly those capable of repopulating bone marrow and sustaining hematopoiesis. This study aimed to discover if hematopoietic progenitor cells were affected by treatment with CAMPATH-1H, with or without human complement. Bone marrow mononuclear cells from healthy volunteers were treated with saturating concentrations of CAMPATH-1H, human complement, or CAMPATH-1H plus human complement. The CD34-positive fraction of the mononuclear cells was treated similarly. Residual progenitor activity was measured in the colony-forming unit-granulocyte, erythroid, monocyte, megakaryocyte assay and compared with untreated controls. There was no significant difference (at the 5% level) between treated and control cells. Mononuclear cells were divided into CAMPATH-1H-positive and CAMPATH-1H-negative fractions by fluorescein isothiocyanate-CAMPATH-1H labeling and fluorescence-activated cell sorter separation. Hematopoietic progenitors were predominantly found in the CAMPATH-1H-negative fraction. Furthermore, mononuclear cells treated with CAMPATH-1H and complement were equivalent to controls in experiments that investigated the capacity of these cells to form hematopoietic foci in long-term cultures.Citation
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. 1993, 82 (3):807-12 BloodJournal
BloodPubMed ID
7687895Type
ArticleLanguage
enISSN
0006-4971Collections
Related articles
- Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
- Authors: Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H, Brookes S, Pamphilon DH
- Issue date: 2000
- Effect of bone marrow T lymphocytes treated with CAMPATH 1G on megakaryocyte colony formation.
- Authors: Deutsch VR, Nagler A, Slavin S, Condiotti R, Levine RF, Eldor A
- Issue date: 1993 Oct
- The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
- Authors: Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A
- Issue date: 2014
- Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
- Authors: La Russa VF, Griffin JD, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG
- Issue date: 1992 May
- The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
- Authors: Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR
- Issue date: 2000 Apr